

Description

Lipopharma is a pioneering clinical-stage biopharmaceutical company that focuses its activities on the discovery, design and clinical development of a new generation of medicines that act through the selective regulation of membrane lipids, a novel therapeutic strategy known as “Membrane-Lipid Therapy” (MLT). Lipopharma arose as an academic spin-off, founded to turn new scientific breakthroughs and discoveries made by scientists at the University of the Balearic Islands in Mallorca, Spain, into a new class of innovative lipid-regulator therapeutic agents that we believe have dramatic game-changing potential in the treatment of life-threatening conditions like cancer, Alzheimer's disease, inflammatory or metabolic diseases.

Services/Products

LP561A1 (2OHOA), Lipopharma's lead R&D program, is an orally administered synthetic analogue of oleic acid that activates sphingomyelin synthase (SMS) which results in a specific “normalization” of the altered membrane lipid composition of cancer cells. Therefore, it regulates the localization and activity of a number of key peripheral signal transduction proteins, normalizing the activity of critical signalling pathways for the proliferation of cancer cells (Ras/MAPK/PI3k/Akt, cyclin/CDK), inducing stop of cell proliferation and selective death of cancer cells by autophagy (in glioma). The European Medicines Agency designated 2-OHOA as an orphan medicinal product for the treatment of glioma in October 2011 (EU/3/11/916). A phase I/IIa clinical trial of Minerval in Adult Patients with Advanced Solid Tumours including Malignant Glioma (MIN-001-1203) is currently underway and recruiting participants since May 2013. The preliminary results of the adult trial are promising, with clinical responses confirmed in several patients, including advanced glioblastoma patients, while no drug-related toxicities have been found, other than anticipated Gastrointestinal (GI) effects at high doses. LP226A1 is a polyunsaturated fatty acid derivative that was designed with the aim of restoring the membrane lipid structure to prevent the molecular and cellular alterations observed in AD patients. LP204A1 is a polyunsaturated fatty acid derivative that produces a remarkable anti-inflammatory effect in a LPS-challenged mouse model of inflammation, acting through COX1 and COX2. Lipopharma currently investigates the therapeutic applications of new compounds designed on the basis of our innovative Membrane-Lipid Therapy (MLT) know-how: LPA181, LP205A1, LP10218, LP20104 and LP30171.

Market/ Development areas

Oncology. Drug development for the treatment of cancers among them glioma, lung, pancreatic and prostate cancer. Neurodegeneration. Development of drugs for the treatment of neurodegenerative diseases with special emphasis on Alzheimer's disease. Spinal Cord. Drug development to improve mobility in spinal cord injuries. Inflammation. Development of drugs for the treatment of inflammatory and autoimmune diseases. Development of cardio-food and nutraceutical supplements.

Tecnologies

Membrane Lipid Therapy (MLT). An innovative technology that focuses on lipids of cell membranes.

Pipeline

Product	Type of product	Therapeutic Area	Indication	Development Phase
LP226A1	Drug	SNC	Enfermedades neurodegenerativas	Pre-clinical Regulatory/ Preliminary validation
L204A1	Drug	Enfermedades inflamatorias	Inflamación	No pre-clinical regulatory / R+D
LP10218	Drug	Oncología	Cáncer	No pre-clinical regulatory / R+D
LP20104	Drug	Oncología	Cáncer	No pre-clinical regulatory / R+D
LPA181	Drug	SNC	Lesión de Médula Espinal	No pre-clinical regulatory / R+D
LPA205A1	Drug	SNC	Enfermedades neurodegenerativas	No pre-clinical regulatory / R+D
LP30171	Drug	Oncología y Metabolismo	Cáncer y enfermedades metabólicas	No pre-clinical regulatory / R+D

Patents

Product	Type of product	Therapeutic Area	Indication	Development Phase
PCT/ES02/00475	Patent	Oncología y enfermedades cardiovasculares	Cáncer e hipertensión	No pre-clinical regulatory / R+D
P200803480	Patent	Varias	No específica	No pre-clinical regulatory / R+D
PCT/ES2009/070252	Patent	SNC	Lesión de Médula Espinal	No pre-clinical regulatory / R+D
PCT/ES2010/070153	Patent	Varias	No específica	No pre-clinical regulatory / R+D
PCT/ES2012/070697	Patent	Varias	No específica	No pre-clinical regulatory / R+D

Company profile

Founded: 2006
Juridic form: S. L.
Workers:

Directive team:
CEO: Vicenç Tur Tur

Lipopharma Therapeutics S.L.

Crtra. Valldemossa Km. 7,4 - ParcBit - Edifici Dissset - 2º piso. Módulo C-8
CP 07121, Palma de Mallorca
971 43 98 86
info@lipopharma.com

www.lipopharma.com



